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SHOX haploinsufficiency is a frequent cause of short stature. Despite advances 
in sequencing technologies, the identification of SHOX mutations continues to 
be performed using standard methods, including MLPA followed by Sanger 
sequencing. We designed a targeted panel of genes associated with growth 
impairment, including SHOX genomic and enhancer regions, to improve the 
resolution of next-generation sequencing for SHOX analysis. We used two 
software packages, CONTRA and Nexus Copy Number, in addition to visual 
analysis to investigate the presence of copy number variants (CNVs). We 
evaluated 15 patients with previously known SHOX defects, including point 
mutations, deletions and a duplication, and 77 patients with idiopathic short 
stature (ISS). The panel was able to confirm all known defects in the validation 
analysis. During the prospective evaluation, we identified two new partial SHOX 
deletions (one detected only by visual analysis), including an intragenic deletion 
not detected by MLPA. Additionally, we were able to determine the breakpoints 
in four cases. Our results show that the designed panel can be used for the 
molecular investigation of patients with ISS, and it may even detect CNVs in 
SHOX and its enhancers, which may be present in a significant fraction of 
patients. 
 
Key words: growth disorder; short stature; SHOX gene; copy number variants; 
targeted panel sequencing; next-generation sequencing 
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Introduction 
The short stature homeobox (SHOX) gene, located inside the 
pseudoautosomal region 1 of sex chromosomes, encodes a transcriptional 
activator essential for growth plate physiology. SHOX haploinsufficiency is 
considered one of the main monogenic causes of short stature and is a well-
established indication for growth hormone therapy to improve adult height1,2. 
Approximately 2-15% of children classified as idiopathic short stature (ISS) and 
70-90% of patients with Léri-Weill dyschondrosteosis (LWD) have SHOX 
haploinsufficiency1. Despite recent advances in sequencing technologies, the 
molecular investigation of SHOX mutations continues to be performed by 
standard methods, such as multiplex ligation-dependent probe amplification 
(MLPA) analysis followed by gene sequencing3. 
The massively parallel sequencing technologies have increased the 
diagnostic yields in several genetic disorders. The molecular investigation of 
children with short stature of unknown cause has followed this same trend, with 
the simultaneous analysis of multiple genes using exome or targeted panel 
strategies4,5. Considering this scenario, the study of SHOX is a major challenge 
because of the large number of copy number variants (CNVs) and the 
importance of investigating regulatory regions6. 
We designed a targeted panel for next-generation sequencing (NGS) to 
evaluate a cohort of patients with ISS. One of the main challenges of this panel 
would be identifying SHOX defects. For this reason, we included the entire 
genomic SHOX region and its enhancers to improve the resolution of NGS for 
the analysis of this gene. First, we validated this panel by analyzing samples 
from patients with known SHOX CNVs and point mutations. Additionally, we 
prospectively screened SHOX defects in a cohort of patients (n=77) with ISS.  
 
Materials and Methods 
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Patients 
 This study was approved by the local Ethics Committee. Patients or 
guardians gave their informed written consent. Fifteen patients with known 
SHOX defects were selected to evaluate the efficiency of the panel in identifying 
those defects: two patients with point mutations (p.Tyr35* and p.Arg147His), 
nine with different sized heterozygous deletions involving the gene, one with an 
intragenic duplication, and three with deletions located downstream of SHOX  
(Table 1/Supporting Information, Figure S1). Another 77 ISS patients were 
included for a prospective genetic evaluation. None of these patients had 
apparent skeletal disease or evidence of LWD. Thirty-one (31/77;40%) patients 
had had a normal SHOX evaluation by MLPA and Sanger sequencing. 
 
Molecular genetic analysis 
Genomic DNA of the patients was analyzed by a customized panel of 
targeted sequencing based on the Agilent SureSelectXT capture system. In this 
panel, we included the entire genomic region of SHOX and selected up- and 
downstream enhancer regions. DNA libraries were sequenced using Illumina 
platform. 
The raw data were aligned to the reference genome (GRCh37/hg19) with 
BWA tools. Variant calling was performed with Freebayes and annotated with 
ANNOVAR. The variants were filtered as previously described5. CNV analyses 
were performed using two software packages able to call CNVs for target region 
based on the normalized depth of coverage: COpy Number Targeted 
Resequencing Analysis (CONTRA)7 and Nexus Copy Number (BioDiscovery, 
Inc.)8. We also visually inspected SHOX coverage using Integrative Genomics 
Viewer (IGV) software. 
MLPA analysis was carried out using the commercial kit P018-SHOX-G1 
(MRC Holland). Sanger sequencing was used to confirm and determine the 
exact breakpoints observed by panel sequencing.  
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 More details of the Methods are available in the Supporting Information, 
Appendix S1 and Table S1. 
 
Results 
The mean coverage depths for the genomic and SHOX coding regions 
were 357x and 387x, respectively. Among 92 samples (validation:15; 
prospective analysis:77), all coding regions of the main SHOX transcript 
(NM_000451.3) had more than a 20-fold depth of coverage, and 81% of SHOX 
genomic region had more than a 10-fold depth of coverage (Supporting 
Information, Tables S2-S3, Figure S2). 
 
Validation 
Using the aforementioned association of analyzes, our panel was able to 
identify all 16 previously known SHOX mutations. The variant call format (VCF) 
files filtration identified both point mutations. CONTRA analyses were able to 
detect 13 (13/14;93%) known CNVs, and Nexus detected 12 (12/14;86%). 
CONTRA missed the intragenic duplication (Case 12, Figure 1). Nexus was 
able to detect this copy number gain (Figure 1); however, it did not identify the 
deletion located downstream of SHOX in Cases 5 and 15, both detected by 
CONTRA (Supporting Information, Figure S3). 
Through direct visualization of the SHOX region, we confirmed all 14 
CNVs. IGV visualization also enabled the identification of deletion breakpoints 
in some cases (Figure 2): Case 11 had a previously reported intragenic deletion 
involving exons 4, 5 and 6a; however its breakpoints had not been defined9. 
After the IGV visualization, we designed specific primers and sequenced the 
region across the deletion breakpoints. The deletion was defined in 11,722 bp, 
with 4 bp overlapping in both breakpoints. We could also determine the exact 
breakpoints of two probands with deletions in the downstream enhancer region 
(Cases 13 and 14). They have the same 47,543 bp recurrent deletion previously 
identified in several individuals with ISS and LWD10. 
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Prospective evaluation 
We did not identify pathogenic point mutations or small indels in SHOX in 
our cohort of patients with ISS. However, we identified two (2/77;2.6%) new 
partial SHOX deletions. The first one is a new intragenic deletion encompassing 
exon 1 identified in a patient with disproportionate short stature that has not 
been previously screened for SHOX mutations (Case 16). This deletion was 
detected by both CNV software and was also identified in the patients’ mother, 
who also exhibited body disproportion.  
The panel further identified another intragenic deletion involving the last 
20 nucleotides from exon 3 and part of intron 3 (Figure 2) in a patient with 
disproportionate short stature in whose previous SHOX study had been 
negative (Case 17). This deletion was identified by the visual inspection of 
SHOX but was missed in CONTRA and Nexus analyses. The deletion was 
defined in 679 bp; it segregated with the phenotype in the family and was also 
identified in the patient’s father and sister, both with altered body proportions. 
 
Discussion 
The molecular genetic investigation of children with growth disorders has 
gradually gained importance. Since SHOX defects have a relatively high 
frequency and have important clinical implications, proper analysis of this gene 
is essential in this era of multigene sequencing technology. Currently, the 
analysis of SHOX is still performed by MLPA followed by Sanger sequencing of 
the coding region1. This candidate gene approach is feasible for a small number 
of patients with a high probability of harboring a SHOX defect. However, 
patients with SHOX defects frequently lack specific phenotype, and the use of 
NGS is a potential strategy to investigate a large number of patients classified 
as ISS4,5. 
 We evaluated the performance of a targeted panel that can be useful for 
ISS diagnosis without the need for the previous implementation of MLPA for 
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SHOX analysis. Our panel presented good coverage of SHOX coding and 
enhancer regions. The data analysis with CONTRA and Nexus software 
combined with the visual inspection of SHOX resulted in an efficiency of CNV 
detection similar to those reached by standard methods. The panel was able to 
detect all previously known SHOX mutations (two point mutations and 14 
CNVs), including deletions located downstream of SHOX in the enhancer 
region10. It was also able to reveal two novel partial SHOX deletions in the 
prospective analysis, including one deletion (Case 17) previously missed in 
MLPA analysis11.  
CONTRA software presented a sensitivity of 87.5% (14/16) in the 
detection of CNVs. A sensitivity of 68% was described by Li and collaborators 
for CONTRA for deletions of 50-200 bp and of 96.4% for full exon deletions7. 
The sensitivity of Nexus was 81.2% (13/16). The estimated sensitivity for the 
exome-based discovery of rare CNVs containing three or more exons is 
approximately 76%12. Based on this assumption, CONTRA and Nexus analyses 
proved to be satisfactory in detecting CNVs. We believe that the pipeline of 
CNV analyses could be improved by the inclusion of other strategies beyond the 
depth of coverage, such as read-pair and split-read approaches13. 
Visual inspection was essential for the identification of some CNVs and 
for the characterization of breakpoints. Although it does not seem to be the ideal 
method for the analysis of large numbers of samples, it can be useful until we 
have more sensitive software for the detection of CNVs available. We also 
believe that the inclusion of larger regions and other SHOX neighboring genes 
in next versions of the panel may improve the analysis of the CNVs, helping to 
estimate their range sizes. 
Our results demonstrate that this customized targeted panel associated 
with automated CNV analysis and the direct visualization of SHOX sequencing 
is efficient for diagnosing SHOX defects. Using a robust panel that aimed to 
capture SHOX genomic and enhancer regions, we improved the resolution of 
NGS for the study of SHOX. This NGS targeted panel can be useful in the 
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molecular investigation of patients with ISS, allowing the simultaneous analysis 
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Figure Legends  
 
Figure 1: CONTRA and Nexus analyses of Cases 11 and 12. CONTRA (A) and 
Nexus (B) plots of Case 11, which has a heterozygous deletion involving exons 
4, 5 and 6a of SHOX. The plots show dots with log ratios near -1.0 in SHOX 
region, indicating the deletion. In CONTRA plot (A), the dots are indicated by 
the black arrow, while in Nexus (B), they are inside the red region. CONTRA (C) 
and Nexus (D) plots of Case 12, which has a duplication of exons 1, 2 and 3 in 
SHOX. The CONTRA plot (C) in this case shows dots suggestive of a 
duplication; however, the log ratios of these regions were not higher than +0.7 
(used as filtration criteria). The Nexus plot (D), in turn, identified the duplication, 
showing dots with log ratios near +1.0 in regions that correspond to these exons 
(blue region). The black bars and numbers located at the top of Nexus plots (B, 
D) indicate the SHOX exons. 
 
Figure 2: IGV and Sanger sequencing of breakpoint regions in Cases 11 (A, B) 
and 17 (C, D), both with intragenic deletions. In IGV images, the black arrows 
indicate the breakpoints (left arrow indicates the 5’ breakpoints, and right arrow, 
the 3’). The bars and numbers located at the bottom of IGV image (C) indicate 
SHOX exons. Coordinates are according to chromosome X (GRCh37/hg19). 
Sanger sequencing (B, D) defined the exact size of the deletions. 
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Table 1: Results of the CNV analyses of SHOX gene region of 15 validation patients and the two patients with deletions identified prospectively 
 
* Minimum and maximum approximated deletion interval predicted by MLPA results. MLPA was performed with commercial kits available at the time (P018-SHOX-C1, 
D1, E1, G1) (MRC Holland, Amsterdam, Netherlands).  
** This maximum interval must be larger because there is no conserved probe upstream to the first deleted probe. 
§ Size of the deletions and breakpoint positions determined by Sanger sequencing of the cases that had their breakpoints identified. The approximate coordinates are 
according to chromosome X, GRCh37/hg19. 
MLPA: multiplex ligation-dependent probe amplification; F: female; M: male; bp: base pair; Kb: kilobases; Mb: megabases; CNV: copy number variant; +: positive result 
(the methodology was able to identify the CNV); - : negative result (the methodology was not able to identify the CNV). NP: not performed. 
 
 
Case Sex Cohort Mutation MLPA 
Predicted deletion interval* 
CONTRA Nexus IGV Sanger 
Minimum Maximum 
1 F Validation Point Mutation - - - - - + c.440G>A (p.Arg147His) 
2 M Validation Point mutation - - - - - + c.105C>A (p.Tyr35*) 
3 F Validation Large deletion + 6.9 Mb 8.2 Mb** + + + NP 
4 F Validation Large deletion + 1.5 Mb 2.8 Mb** + + + NP 
5 F Validation Large deletion + 1.5 Mb 5.9 Mb** + + + NP 
   Downstream deletion + 113.2 Kb 194.4 Kb + - + NP 
6 M Validation Large deletion + 1.2 Mb 1.5 Mb** + + + NP 
7 M Validation Large deletion + 1.2 Mb 1.5 Mb** + + + NP 
8 F Validation Large deletion + 652.0 Kb 1.1 Mb** + + + NP 
9 M Validation Large deletion + 243.4 Kb 265.4 Kb + + + NP 
10 M Validation Large deletion + 444.2 Kb 501.8 Kb** + + + NP 
11 M Validation Intragenic deletion + 3.8 Kb 16.3 Kb + + + 11,722 bp; ChrX:596,149-607,872§ 
12 F Validation Intragenic duplication + 15.0 Kb 294.1 Kb - + + NP 
13 F Validation Downstream deletion + 36.6 Kb 76.8 Kb + + + 47,543 bp; ChrX:780,549-828,093§ 
14 F Validation Downstream deletion + 36.6 Kb 76.8 Kb + + + 47,543 bp; ChrX:780,549-828,093§ 
15 F Validation Downstream deletion + 113.2 Kb 194.4 Kb + - + NP 
16 F Prospective analysis Intragenic deletion + 64 bp 11.3 Kb + + + NP 
17 F Prospective analysis Intragenic deletion - - - - - + 679 bp; ChrX:595,541-596-221§ 
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